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Abstract:  Thioredoxin reductase (TrxR) is an essential enzyme required 
for the efficient maintenance of the cellular redox homeostasis, particu-
larly in cancer cells that are sensitive to reactive oxygen species. In mam-
mals, distinct isozymes function in the cytosol and mitochondria. Through 
an intricate mechanism, these enzymes transfer reducing equivalents 
from NADPH to bound FAD and subsequently to an active-site disulfide. In 
mammalian TrxRs, the dithiol then reduces a mobile C-terminal selenocys-
teine-containing tetrapeptide of the opposing subunit of the dimer. Once 
activated, the C-terminal redox center reduces a disulfide bond within thio-
redoxin. In this report, we present the structural data on a mitochondrial 
TrxR, TrxR2 (also known as TR3 and TxnRd2). Mouse TrxR2, in which the 
essential selenocysteine residue had been replaced with cysteine, was iso-
lated as a FAD-containing holoenzyme and crystallized (2.6 Å; R = 22.2%; 
Rfree =
 27.6%). The addition of NADPH to the TrxR2 crystals resulted in a 
color change, indicating reduction of the active-site disulfide and forma-
tion of a species presumed to be the flavin–thiolate charge transfer com-
plex. Examination of the NADP(H)-bound model (3.0 Å; R = 24.1%; Rfree 
= 31.2%) indicates that an active-site tyrosine residue must rotate from 
its initial position to stack against the nicotinamide ring of NADPH, which 
is juxtaposed to the isoalloxazine ring of FAD to facilitate hydride trans-
fer. Detailed analysis of the structural data in conjunction with a model 
of the unusual C-terminal selenenylsulfide suggests molecular details of 
the reaction mechanism and highlights evolutionary adaptations among 
reductases. 
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Thioredoxins are the major cellular protein disulfide reductases and are responsible for the regulation of  numerous biochemical pro-
cesses within the cell (1). These proteins are maintained in a reduced 
state by thioredoxin reductases (TrxR), homodimeric f  lavoproteins that 
catalyze the NADPH-dependent reduction of  thioredoxins (2, 3). 
Trx-S2 + NADPH + H
+ → Trx-(SH)2 + NADP
+.
Two forms of  TrxRs have evolved with related but distinct modes 
of  catalysis (2–5). Low-Mr TrxRs (Mr ≈35 kDa) are typically
 found in 
prokaryotes, archaea, plants, and lower eukaryotes, whereas high-Mr 
TrxRs (Mr ≈55 kDa) are observed in higher eukaryotes.
 To date, only 
the green algae Chlamydomonas reinhardtii has been shown to contain 
both a low- and a high-Mr TrxR (6).
 
The general features of  catalysis are retained in both low- and high-
Mr TrxR (2, 4). TrxR transfers reducing equivalents
 from NADPH to its 
bound FAD, ultimately leading to the reduction of  an active-site disul-
fide. In low-Mr TrxRs, the catalytic
 cycle requires a large conformational 
change after dithiol activation (4, 7, 8). In high-Mr TrxR, the active-site 
dithiol reduces a third redox active center in the highly mobile C ter-
minus of  the opposing subunit. This third group is responsible for the 
reduction of  the disulfide bond within thioredoxin. Its nature is spe-
cies-specific and ranges from a C-X-X-X-X-C disulfide in Plasmodium 
falciparum (9) to a vicinal disulfide in Drosophila melanogaster (10) or a vici-
nal selenenylsulfide in mammalian TrxRs (11, 12). 
In mammalian systems, three isozymes of  high-Mr TrxRs have been
 
identified: a cytosolic (TrxR1) (11, 12), a mitochondrial (TrxR2) (13), 
and an isozyme highly expressed in testes (14, 15). Targeted disruption 
of  either TrxR1 (16) or TrxR2 (17) genes results in an embryonic lethal 
phenotype, and TrxR1 and TrxR2 appear to have nonredundant func-
tions (16–19). TrxR1 null embryos are affected primarily by compro-
mised cell proliferation (16), whereas TrxR2 null embryos suffer from 
severe anemia and improper heart development (17). Splice variants 
of  TrxR1 and TrxR2 have also been identified, including a variant that 
would result in the targeting of  TrxR2 to the cytosol (20–24). However, 
the biological implications of  these variations have not been resolved 
and would benefit from additional biochemical and structural character-
izations of  the enzymes. 
Numerous biochemical and computational studies have added to 
our understanding of  the catalytic mechanism of  high-Mr TrxR
 (2–5, 
15, 25–28). Reduction of  the enzyme by a single equivalent of  NADPH 
leads to several two-electron reduced species (EH2), with a thiolate–
flavin charge transfer complex predominating. Addition of  a second 
equivalent of  NADPH leads to a four-electron reduced enzyme (EH4) 
in which both the active-site disulfide and the selenosulfide-contain-
ing C-terminal tail of  the opposing subunit are likely reduced. Once re-
duced to the EH4 state, the enzyme catalyzes a disulfide exchange be-
tween the activated C-terminal tail and oxidized thioredoxin. To date, 
the molecular details of  selenenylsulfide/disulfide exchange have not 
been determined. 
Recently, the first x-ray structure of  a high-Mr TrxR, rat cytosolic
 
TrxR1, was described (29). The overall topology of  this enzyme is sim-
ilar to that of  other pyridine nucleotide disulfide oxidoreductases, par-
ticularly glutathione reductases (30–35), and is in agreement with earlier 
modeling studies of  high-Mr TrxRs (15).
 Interestingly, all of  the resi-
dues in glutathione reductase responsible for substrate recognition are 
structurally conserved in rTrxR1, even though rTrxR1 cannot directly 
reduce oxidized glutathione. The authors (15) suggested that the mobile 
selenenylsulfide containing a C-terminal tail not only serves as a third 
redox active group, but it also blocks oxidized glutathione from bind-
ing to the enzyme. In addition, the structure confirmed the obligatory 
“head-to-tail” arrangement of  high-Mr TrxR, with the redox-active
 C-
terminal tail of  one subunit interacting with the active site of  the op-
posing subunit (36, 37). Unfortunately, the observed conformation of  
the C-terminal tail precluded direct interaction with the active-site di-
sulfide/dithiol group, suggesting an additional catalytically competent 
structural arrangement must exist. 
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To further investigate the mechanisms of  mammalian TrxR en-
zymes, we have determined the structure of  a mitochondrial TrxR. In 
this report, the structural features of  mouse FAD-containing TrxR2 in 
the absence and presence of  NADPH are described. The conforma-
tional changes that accompany pyridine nucleotide binding and reduc-
tion of  the enzyme are revealed by comparative inspection of  these two 
structures. Comparisons between mitochondrial and cytosolic isoen-
zymes suggest potential differences in enzymatic activities and provide 
additional insights into the catalytic mechanism of  high-Mr TrxRs.
 
Materials and Methods
Data Collection and Structure Determination. Mature mouse TrxR 
Sec-523-Cys (mTrxR2) was expressed in Escherichia coli, purified by af-
finity chromatography, and crystallized as described in the “Support-
ing Text” section. Diffraction data for mTrxR2 holoenzyme and the 
mTrxR2–NADP(H) complex were collected by using radiation pro-
duced by a Rigaku (Tokyo) MicroMax-007 x-ray generator fitted with 
confocal blue optics and an R axis IV++ image plate system. Crystals 
were maintained under cryogenic conditions by an X-stream cooling 
system, and data were analyzed with the crystal clear software pack-
age (Molecular Structure, The Woodlands, TX) (38). The structure of  
mTrxR2 with its bound FAD was determined by molecular replace-
ment by using the crystallography and nmr system software pack-
age (39) and rat TrxR1 (1H6V) (29) as the search molecule (≈55% se-
quence identity). An unambiguous solution was obtained with an initial 
R of  39.4% (Rfree = 40.6%), after
 rigid body refinement. The result-
ing phase information produced a readily interpretable electron density 
map containing significant positive density within the active site of  the 
enzyme, corresponding to the omitted FAD molecule (not shown). The 
mTrxR2–NADP(H) complex was isomorphous with the mTrxR2–FAD 
structure, and the same Rfree test set (10%) was used in the refinement
 
of  each structure. 
Model Building and Refinement. Models were refined by using the 
crystallography and nmr system (39) and rebuilt after each round of  
refinement by using the program O (40). Ambiguous regions of  the 
electron density map were evaluated by using 2Fo–Fc
 simulated anneal-
ing omit maps. As the model neared completion, bound cofactors and 
water molecules obeying proper hydrogen-bonding constraints with 
electron densities >1.0 σ on a 2Fo–Fc
 map and 3.0 σ on an Fo–Fc map 
were also included. Model geometry was monitored by using molpro-
bity (41), and Figures 1, 2, 3, 4, 5 were generated by using the program 
chimera (University of  California, San Francisco) (42). 
Modeling of  the C-Terminal Tail of  mTrxR2. The C-terminal tail 
of  mTrxR2 is highly mobile, consistent with its role in the transfer of  
reducing equivalents from deep within the enzyme molecule to an ac-
tive-site disulfide in thioredoxin. The electron density for both mTrxR2 
structures was quite poor beyond Thr-518. However, weak back-
bone density for Val-519 and Thr-520 was observed in the mTrxR2–
NADP(H) complex and suggested an orientation of  the C-terminal tail 
of  mTrxR2. Vicinal disulfide bonds are relatively rare in the available 
protein structures, and the vast majority are found in type VIII β turns 
(43). To model the selenenylsulfide in oxidized mTrxR2, we used the 
vicinal disulfide turn motif  within methanol dehydrogenase as a tem-
plate (44). This prototype motif  allowed us to model the relative po-
sitions of  Gly-521, Cys-522, Sec-523, and Gly-524, and the absolute 
placement of  the C-terminal tail was done manually, optimizing interac-
tions within the active site of  mTrxR2 and maintaining reasonable geo-
metric constraints. 
Results and Discussion
Structure Determination and Model Quality. The structure of  
mouse TrxR2 was determined by molecular replacement by using the 
related rat cytosolic TrxR1 as a probe (29). A readily interpretable elec-
tron density map was obtained, and density was clearly observed for 
the protein-bound FAD molecule (data not shown). To verify the so-
lution, a simulated annealing omit map was constructed, omitting res-
idues within 5 Å of  the proposed FAD-binding site. Strong positive 
density was observed for FAD, as well as the additional atoms omitted 
from the map calculation, indicating a correct molecular replacement 
solution (supplemental Figure 6).
Table 1. Data collection and refinement statistics for the mTrxR2 structures
15020 Biterova, turanov, Gladyshev, & BaryCki in PNAS 102 (2005) 
mTrxR2 crystals belong to spacegroup I4122 and contain single
 sub-
unit of  the dimeric enzyme in the asymmetric unit. Statistics for the fi-
nal mTrxR2–FAD model are given in Table 1. Ramachandran plot anal-
ysis by molprobity (41) indicated that the final model had 91% of  its 
residues in the favored region and >99% in the allowed region. The 
model had an overall B factor of  57.2 Å2, reflecting high overall ther-
mal motion within the crystal. The twofold symmetry of  the dimeric 
enzyme corresponds to a crystallographic axis and contains extensive 
intersubunit contacts (Figure 1). The N terminus of  the mTrxR2 and 
the final six residues of  the polypeptide chain are not observed in the 
electron density map. Furthermore, three regions of  the model, corre-
sponding to residues 158–182, 282–307, and 321–340, exhibit consid-
erable motion as evidenced by consecutive B factors >80 Å2. These re-
gions had similar mobility in the structure of  mTrxR2 in complex with 
NADP(H), as discussed below (Figure 2). Considerably fewer crystal 
packing contacts are observed at the extremes of  the NADP(H) and 
FAD-binding domains and may account for the greater thermal motion 
observed in these regions. Although significant electron density exists 
for these surface-exposed residues, the exact atom placements should 
be evaluated with care. 
Overall Structure. The structure of  mTrxR2 is comparable to that of  
other pyridine nucleotide disulfide reductases (30–34). As described for 
rTrxR1 (29), mammalian TrxR is comprised of  three domains: a FAD-
binding domain (mTrxR2 residues 35–190, 322–392), an NADPH-
binding domain (mTrxR2 residues 191–321), and an interface domain 
(mTxrR2 residues 393–524) (Figures 1 and 2). Comparison of  mTrxR2 
with the related rTrxR1 reveals that the two enzymes have very similar 
structures (rms deviation for Cα = 0.79 Å). A significant difference is 
the presence of  a surface-exposed intersubunit disulfide bond between 
Cys-483 in the two subunits of  mTrxR2. This cysteine is highly con-
served among mammalian TrxRs and is located near the end of  a he-
lix (α11 in rTrxR1) in the interface domain (Figure 1). A nonreducing 
SDS gel of  mTrxR2 indicates that only ≈10% of  the protein is involved 
in an intersubunit disulfide bond (data not shown), suggesting that the 
crystallization conditions may promote this disulfide bond formation. 
Interestingly, the corresponding cysteine in rTrxR1, Cys-458, is found 
in a similar position but in a reduced state (29). An intriguing possibil-
ity is that Cys-483 represents a third dithiol/disulfide pair in the enzyme 
with as-yet-unidentified function. 
NADPH-Binding Site. To identify the cofactor-binding site in the 
enzyme, mTrxR2 holoenzyme crystals were transferred to an artificial 
mother liquor containing NADPH. A striking color change was ob-
served: the yellow mTrxR2 crystals became a deep red (Figure 7, which 
is published as supporting information on the PNAS web site), sug-
gesting the formation of  a charge-transfer complex with the addition 
of  NADPH. As part of  the proposed catalytic mechanism, reduction 
of  the active-site disulfide results in the formation of  a charge-trans-
fer complex between FAD and an active-site thiolate (2, 4, 25–27). It is 
important to note that the excess NADPH added to the crystal can dis-
place the resulting oxidized cofactor without disruption of  the charge-
transfer complex (25). Therefore, we cannot unambiguously state 
whether NADP+ or NADPH is bound in the active site and thus desig-
nate the cofactor as NADP(H). Furthermore, to account for the charge-
transfer complex, the active-site cysteine residues of  mTrxR2, Cys-86, 
and Cys-91 were modeled in the reduced state, such that the sulfur of  
Cys-91 is in close proximity to C4A of  the flavin ring (≈3.4 Å). 
Because of  the moderate resolution of  the structure (3.0 Å), an ex-
amination of  the electron density per se cannot exclude the possibility of  
a disulfide between Cys-86 and Cys-91. However, modeling of  a disul-
fide bond between Cys-86 and Cys-91 in the mTrxR2–NADP(H) com-
plex results in several difference peaks in the corresponding region of  
the Fo–Fc map, suggesting
 that the modeled disulfide does not agree 
well with the x-ray data (data not shown). Furthermore, comparison 
of  the mTrxR2 holoenzyme and mTrxR2–NADP(H) complex by ex-
amination of  a difference Fourier electron density map suggests mod-
est differences in the placement of  Cys-86 and Cys-91, consistent with 
reduction of  the disulfide (data not shown). The final model of  the 
mTrxR2–NADP(H) complex is shown in Figure 2, and model statistics 
are provided in Table 1. 
Overall, the mTrxR2–NADP(H) and the mTrxR2 holoenzyme struc-
tures are very similar, with rms deviation for Cα = 0.45 Å. As with the 
oxidized mTrxR2 structure, residues at the dimer interface and within 
the core of  the active site exhibit considerably lower B factors than res-
idues at the extreme edges of  the FAD- and NADPH-binding domains 
(Figure 2). These highly mobile regions do not appear to have a direct 
role in catalysis and correspond to more divergent regions of  high-Mr 
Figure 1. Ribbon representation of the overall structure of the mTrxR2 ho-
loenzyme. Subunit A is shown in dark colors, and subunit B is shown in 
light colors. The protein is comprised of three domains: a FAD-binding do-
main (yellow), an NADP(H)-binding domain (green), and an interface do-
main (blue). Bound FAD molecules are represented as space-filling models 
with carbon atoms colored in gray, nitrogen atoms in blue, oxygen atoms 
in red, and phosphorous atoms in cyan. Side chains of Cys-483 in each 
subunit, located at the dimer interface, are shown in space-filling models 
with sulfur atoms colored in yellow (center). 
Figure 2. Structure of mTrxR2 in complex with NADP(H). The ribbon rep-
resentation of mTrxR2 is shown in an orientation similar to Figure 1. FAD 
and NADP(H) are shown as space-filling models and are colored yellow and 
green, respectively. The ribbon is colored according to the average B fac-
tor of its corresponding residue. Values range from 20 (dark blue) to 100 
(dark red) Å2, with an average B factor for the model of 61.7 Å2 (white). 
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TrxR primary structure. To reduce the bias introduced by a direct com-
parison of  the mTrxR2 holoenzyme and mTrxR2–NADP(H) models, 
a difference Fourier electron density map was calculated by using the 
phases from the mTrxR2 holoenzyme. This Fo–Fo map
 was used to as-
sess the structural changes in mTrxR2 on addition of  NADPH (Figure 
3). Continuous electron density was observed for the NADP(H) cofac-
tor, although the quality of  the map in the region of  the nicotinamide 
ring was somewhat degraded by the placement of  Tyr-228 in the ox-
idized mTrxR2 model. The positions of  the isoalloxazine rings from 
each complex were nearly identical, and both ring systems were essen-
tially planar. 
Several significant displacements are observed in the mTrxR2–
NADP(H) protein structure. Two arginine residues, Arg-249 and Arg-
254, reorient to interact with the 2’-phosphate group of  NADPH and 
likely confer the enzyme’s specificity for NADPH relative to NADH 
(29). In addition, the hydroxyl group of  Ser-227 must adjust to allow 
binding of  one of  the bridging phosphate groups of  NADPH. Last, 
the Fo–Fo map indicates that the side chain
 of  Tyr-228 must rotate to 
accommodate NADPH. Thus, to orchestrate this critical catalytic event, 
Tyr-228, which normally shields the flavin ring of  FAD from solvent in 
the absence of  NADPH, must reposition itself  to stack against the nic-
otinamide ring upon cofactor binding. A conserved tyrosine residue in 
human glutathione reductase, Tyr-197, has been shown to serve a com-
parable function (34, 45–47). 
The importance of  such a rotation of  the conserved tyrosine resi-
due upon pyridine nucleotide binding is illustrated by examination of  
the rTrxR1 structure (29). Density is not observed for the nicotinamide 
ring of  NADP+ in the oxidized rTrxR1–NADP+ complex. The equiva-
lent tyrosine residue, Tyr-200, is arranged to shield the flavin ring from 
solvent (Figure 4A, blue model) and thus precludes efficient binding 
of  NADP+. Only the adenosine portions of  each cofactor have similar 
orientations in the rTrxR1 and mTrxR2 structures. The bridging phos-
phate groups and the nicotinamide ribose of  rTrxR1-bound NADP+ 
are displaced significantly relative to the corresponding atoms in the 
mTrxR2–NADP(H) structure. Without reorientation of  the conserved 
tyrosine residue, the nicotinamide and isoalloxazine rings cannot stack 
in the position necessary for hydride transfer. 
Active Site of  mTrxR2. The overall architecture of  the mTrxR2 ac-
tive site is comparable to that of  rTrxR1 (Figure 4B) (29) and human 
glutathione reductase (31, 34, 46). In the mTrxR2–NADP(H) complex, 
the active-site disulfide/dithiol pair is observed in the reduced state, 
whereas this active-site redox center is found in the oxidized state in 
both the mTrxR2 holoenzyme (Figure 1) and the rTrxR1–NADP+ 
complex (Figure 4B). In addition to the active-site disulfide/dithiol 
functional group, a histidine–glutamate pair is located in similar orienta-
tions in these enzymes (H497*-E502* in mTrxR2; an asterisk designates 
an amino acid from the opposing subunit). Mutagenesis studies have 
demonstrated that both cysteine residues, as well as the active-site his-
tidine residue, are essential for efficient catalysis (27). Other functional 
groups of  mTrxR2 that face into the enzyme active site include Lys-
56, His-143, Glu-503*, and Lys-506*. Glu-503* and Lys-506* are po-
Figure 3. Difference Fourier electron density map of the NADP(H)-binding 
site. Shown in the stereodiagram is the difference map contoured at ≈3 σ, 
super-imposed with the final mTrxR2–NADP(H) model. Carbon atoms are 
colored in green, nitrogen atoms in blue, oxygen atoms in red, and phos-
phorous atoms in cyan. For comparison, the final model of the mTrxR2 ho-
loenzyme is also shown (light blue). 
Figure 4. Comparison of the active sites of mTrxR2 and rTrxR1. Models of 
mTrxR2 and rTrxR1 were superimposed and are shown as stick represen-
tations by using the color scheme described in Figure 3. (A) NADP(H)-bind-
ing site. In mTrxR2 (green), the nicotinamide ring of NADP(H) is stacked 
above the isoalloxazine ring of FAD, but it is not observed in rTrxR1(blue), 
because its binding site is occupied by the side chain of Tyr-200. (B) Re-
gion adjacent to the active-site disulfide/dithiol pair. Amino acid side 
chains of mTrxR2 are labeled with the corresponding residues from rTrxR1 
given in parentheses. An asterisk denotes an amino acid residue from the 
opposing subunit of the dimer. Please note that, for FAD, only the isoallox-
azine ring is presented. Thr-368 of mTrxR2 and Thr-339 of rTrxR1 adopt 
nearly identical conformation and have been omitted for clarity. 
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sitioned to form a salt bridge and may stabilize the placement of  Glu-
502*. Such an interaction is absent in human glutathione reductase and 
rTrxR1, but other hydrogen bond networks maintain the tertiary struc-
ture in this region. The epsilon amino group of  Lys-56 is located ≈3.1 
Å from ND1 of  His-143 and may help position the imidazole ring. In-
terestingly, a tyrosine residue replaces His-143 in both human glutathi-
one reductase (Tyr-114) and rTrxR1 (Tyr-116; Figure 4B). This tyrosine 
residue has been implicated in catalysis (47), as discussed below, and 
thus substitution with a histidine residue may modulate the catalytic ac-
tivity of  mTrxR2 relative to these homologues. 
Modeling of  the Redox-Active C-Terminal Tail. The molecular de-
tails of  how reducing equivalents are transferred from the disulfide/
dithiol pair deep within the active site, to the mobile C-terminal tail 
containing the Gly-Cys-Sec-Gly motif, and ultimately to oxidized thio-
redoxin remain unresolved. In the structure of  the rat cytosolic isozyme 
(29), the C terminus was arranged in such a conformation that the se-
lenocysteine residue could not interact with the active-site disulfide/
dithiol, suggesting that an alternate conformation for the C terminus 
must exist. In the current study, the C-terminal tail of  mTrxR2 exhib-
its considerable conformational flexibility, as evidenced by the high B 
factors of  its residues. Furthermore, the last four residues are not ob-
served in the electron density. 
The Gly-Cys-Sec-Gly motif  of  the mTrxR2-NADP(H) structure 
has been modeled into the active site of  the enzyme (Figure 5). A suit-
able template for the selenenylsulfide was identified, and the C terminus 
of  the enzyme was positioned in the active site of  the opposing sub-
unit, optimizing interactions and minimizing geometric strains. Possible 
conformations were limited by the observed position of  residues 518–
520 of  the mTrxR2–NADP(H) structure. Although additional confor-
mations are certainly possible given the highly mobile nature of  this re-
gion of  the protein (29), the model is consistent with several lines of  
biochemical evidence, as discussed below, and is a reasonable starting 
point for biochemical studies aimed at elucidating the precise mecha-
nism of  the enzyme. The eight-membered ring structure of  the sele-
nenylsulfide is juxtaposed to Cys-86 of  the active-site disulfide/dithiol 
(Figure 5). The selenium atom of  selenocysteine 523* is located nearly 
equidistant from the sulfur of  Cys-86 and the epsilon nitrogen of  His-
497*. Similarly, the sulfur of  Cys-522* is adjacent to the epsilon nitro-
gen of  His-143. Last, the carboxylate of  Gly-524* may interact with the 
positively charged side chain of  Lys-506* (not shown). 
Implications for Catalysis. The precise mechanism of  selenenyl-
sulfide/disulfide exchange has not yet been determined for mamma-
lian TrxRs, but studies of  D. melanogaster (DmTrxR1) (26, 48, 49) and 
P. falciparum (27, 37, 50) high-Mr TrxRs provide considerable insight. 
DmTrxR1 exhibits significant sequence homology to mammalian TrxRs 
but is not a selenoprotein (26, 48). It exhibits the salient features of  ca-
talysis described for selenocysteine-containing TrxRs but instead has a 
Ser-Cys-Cys-Ser motif  at its C terminus. Bauer et al. (26) have identified 
Cys-57 and Cys-490* (equivalent to Cys-86 and Sec-523* in mTrxR2) as 
the two thiol groups involved in dithiol/disulfide exchange (26). Simi-
larly, studies with P. falciparum TrxR have suggested that Cys 540* (com-
parable to Sec-523* in mTrxR2) is the C-terminal interchange thiol (27). 
The presented model of  the C-terminal tail of  mTrxR2 within the en-
zyme active site is consistent with Sec-523* interacting with active site 
dithiol/disulfide via Cys-86. After reduction of  the selenenylsulfide, the 
resulting selenolate likely attacks the disulfide of  oxidized thioredoxin 
(29), although this has not yet been experimentally confirmed. 
This placement of  the redox active C-terminal tail suggests several 
active-site residues that may facilitate catalysis (Figure 5). An active-site 
glutamate–histidine pair is conserved in high-Mr TrxRs and is thought 
to promote reduction of  the selenenylsulfide by stabilizing the result-
ing negative charge on the selenolate (28). Mutagenesis studies involv-
ing the analogous glutamate–histidine pair in P. falciparum TrxR have 
demonstrated that this histidine is required for efficient catalysis (27). In 
the mTrxR2 structure in which the C-terminal selenenylsulfide has been 
modeled (Figure 5), the epsilon nitrogen of  His 497* is located nearly 
equidistant from the sulfur of  Cys-86 and the selenium of  Sec-523* and 
is consistent with His-497* being involved in catalysis. 
A second active-site histidine is observed in mTrxR2 that may con-
tribute to catalysis. The epsilon nitrogen of  His-143 is located ≈3 Å 
from the modeled sulfur of  Cys-522*, and its imidazole ring appears to 
be oriented by an adjacent lysine residue, Lys-56 (Figure 5). Interestingly, 
His-143 is replaced with a tyrosine residue in rTrxR1 (Tyr 116; Figure 
4B) and glutathione reductase (Tyr-114). Site-directed mutagenesis stud-
ies in which Tyr-114 of  glutathione reductase has been replaced with a 
leucine residue indicate that Tyr-114 is indeed involved in catalysis (47). 
The Y114L mutant exhibits a nearly 7-fold reduction in specific activity, 
and although not required for catalysis, Tyr-114 contributes to enzymatic 
efficiency. This observation, in concert with the proposed model, sug-
gests that His-143 may be involved in the mechanism of  mTrxR2. How-
ever, additional site-directed mutagenesis and kinetic studies will be re-
quired to assess the exact impact of  His-143 on catalysis. 
The thioredoxin-binding site of  TrxR is thought to be located in the 
cleft between the FAD-binding domain and the dimer interface domain, 
near the C terminus of  the enzyme (Figures 1 and 2). In the absence of  
a high-Mr TrxR/thioredoxin complex structure,
 modeling studies have 
suggested interactions that mediate substrate recognition by TrxR (15, 
Figure 5. Model of the C terminus of mTrxR2. Continuous density was not observed for the final four residues of the mTrxR2–NADP(H) structure, confirm-
ing its highly mobile nature. Thus, residues G521, C522, U523, and G524 were modeled into the active site. In the stereodiagram, the selenium atom 
is colored in pink, nitrogen atoms in blue, oxygen atoms in red, and sulfur atoms in yellow. Carbon atoms from subunit A are colored in green, and those 
from subunit B are in blue and are designated with asterisks. Modeled residues are labeled in red. For clarity, only the nicotinamide ring of NADP(H) and 
the isoallozaine ring of FAD are presented. 
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28, 29). For rTrxR1, several amino acid side chains in the region com-
prised of  residues 115–124 and the C-terminal tail were suggested to 
interact with thioredoxin (29). The corresponding regions in mTrxR2 
(residues 142–151) have similar structural motifs but do exhibit some 
sequence variability. These differences may reflect different recognition 
residues on their respective thioredoxin substrates. However, without 
detailed structural information about the protein–protein complex, it 
remains difficult to ascribe function to particular residues. 
Conclusion
Comparisons of  mTrxR2 structures in the presence and absence of  
NADPH reveal several structural rearrangements that occur upon bind-
ing of  the reduced pyridine nucleotide and suggest that an active-site ty-
rosine residue, Tyr-228, is essential for optimal placement of  the nico-
tinamide ring of  NADPH. Although mTrxR2 maintains the overall 
topology observed in cytosolic rat TrxR, several key active-site residues 
have been replaced. These substitutions probably impact enzymatic ac-
tivity, but the importance of  specific active-site residues to catalytic effi-
ciency will need to be evaluated by site-directed mutagenesis and kinetic 
studies. In addition, a potential redox regulatory center has been identi-
fied that involves Cys-483 residues on opposing subunits. Collectively, 
these insights provided by examination of  the reported crystal structures 
will assist in the design of  further mechanistic studies of  high-Mr TrxRs.
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Figure 6. Fo-Fc omit map in the region of the FAD-binding site. A simulated annealing Fo-Fc 
omit map was generated, omitting residues within 5 Å of the proposed FAD-binding site, as 
described in the text. The resulting electron density is contoured at ≈3 σ and is superimposed 
with the final FAD model in the stereodiagram. Carbon and phosphorus atoms are shown in 
black; oxygen and nitrogen atoms are presented in grey. Protein atoms in this region of the 
map have been omitted for clarity. 




Figure 7. Crystals of mTrxR2. Crystals of mTrxR2 were grown by the sitting-drop method out 
of a solution of 100 mM 2-(N-morpholino)ethanesulfonic acid, pH 6.5, within the precipitant 
range of 22-26% polyethylene glycol 550 monomethyl ether. (A) A crystal of FAD-bound 
mTrxR2 holoenzyme exhibits a characteristic yellow color. (B) The crystal in A was transferred 
to artificial mother liquor containing 5 mM NADPH. Within seconds, the crystal changed to a 
deep red color, consistent with reduction of the active-site disulfide and formation of an FAD-






Generation of the mTrxR2 Expression Construct. The ORF of the mouse TrxR2 (1, 2) 
from nucleotides 131-1615 (corresponding to the sequence of mature protein 
without its mitochondrial signal peptide) was amplified from a mouse cDNA library by 
PCR. The sense primer was 5'-ATTTATAGTCAGCGCGAGTGCAGCGGGAGGGC-3' (NheI 
site is underlined). The antisense mutant primer was 5'-ACGGCGAATTCTTAGCCGCAGC 
AACCAGTCAC-3' (EcoRI site is underlined). In addition, the selenocysteine codon 
(TGA) was altered to Cys (TGC) to facilitate efficient production of the enzyme in 
Escherichia coli. The amplified PCR product was digested with NheI and EcoRI and 
ligated into similarly digested pET28a, a prokaryotic expression vector incorporating a 
cleavable N-terminal His tag (Novagen). Upon isolation of the expression vector, its 
sequence, including the cysteine substitution, was verified (Genomics Core Research 
Facility, University of Nebraska, Lincoln, NE). 
 
Overexpression and Purification of mTrxR2. The plasmid was used to transform E. 
coli strain BL21(DE3) (Novagen). Cultures were grown to an A600 of 0.6-0.8 in LB 
media containing 50 mg/liter kanamycin at 30°C and then were induced overnight 
by the addition of isopropyl-1-thio-d-galactopyranoside to a final concentration of 0.5 
mM. The cells were harvested by centrifugation and stored at -80°C until used. E. 
coli cells were resuspended in cold 50 mM sodium phosphate, pH 8.0/150 mM 
NaCl, containing Protease Inhibitor Mixture EDTA-free (Roche Diagnostics, 
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Mannheim, Germany) and disrupted by sonication. After centrifugation for 30 min at 
27,000 × g at 4°C, the supernatant was collected and loaded onto an immobilized 
metal affinity column (TALON, Clontech) equilibrated with 50 mM sodium phosphate, 
pH 8.0/150 mM NaCl. The recombinant protein was eluted with linear gradient from 
20 to 200 mM of imidazole. Fractions containing mTrxR2 were pooled and dialyzed 
against PBS buffer and applied to a 2', 5'-ADP-Sepharose column (Amersham 
Pharmacia). The bound protein was eluted by the addition of 1 M of NaCl to the 
buffer. Fractions containing the purified mTrxR2 protein were dialyzed against 25 mM 
Tris, pH 8.0/100 mM NaCl, concentrated, and flash frozen at -80°C. 
 
Crystallization and Data Collection. Crystals of mTrxR2 holoenzyme were grown at 
18°C by the sitting-drop method out of a solution of 100 mM 2-(N-
morpholino)ethanesulfonic acid, pH 6.5, within the precipitant range of 22–26% 
polyethylene glycol 550 monomethyl ether at a protein concentration of 10.4 mg/ml. 
Typically, crystals reached a final size of 0.1 × 0.1 × 0.15 mm in 7-10 days and 
exhibited a yellow color, characteristic of flavin-containing proteins. To collect data at 
cryogenic temperatures, crystals were transferred to artificial mother liquor 
containing cryoprotectant (3). This was accomplished in a stepwise fashion by 
soaking the crystals for 1-2 min in artificial mother liquor containing increasing 
amounts of glycerol (5% increments) until a final glycerol concentration of 30% was 
attained. Additionally, NADPH was included in the final soak solution at a 
concentration of 5 mM to obtain the mTrxR2-NADP(H) complex. 
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